Search

Your search keyword '"Nagata, Kayoko"' showing total 24 results
Start Over Author "Nagata, Kayoko" Search Limiters Full Text
24 results on '"Nagata, Kayoko"'

1. Virological characteristics of a SARS-CoV-2-related bat coronavirus, BANAL-20-236

Author

Sawa, Hirofumi, Mizuma, Keita, Li, Jingshu, Mimura, Yume, Ohari, Yuma, Tsubo, Tomoya, Ferdous, Zannatul, Shishido, Kenji, Mohri, Hiromi, Iida, Miki, Tsujino, Shuhei, Misawa, Naoko, Usui, Kaoru, Saikruang, Wilaiporn, Lytras, Spyridon, Kawakubo, Shusuke, Nishumura, Luca, Mendoza Tolentino, Jarel Elgin, Li, Wenye, Yo, Maximilian Stanley, Horinaka, Kio, Suganami, Mai, Chiba, Mika, Yoshimura, Ryo, Yasuda, Kyoko, Iida, Keiko, Strange, Adam Patrick, Ohsumi, Naomi, Tanaka, Shiho, Ogawa, Eiko, Okumura, Kaho, Fukuda, Tsuki, Osujo, Rina, Yoshida, Isao, Nakagawa, So, Takaori-Kondo, Akifumi, Shirakawa, Kotaro, Nagata, Kayoko, Nomura, Ryosuke, Horisawa, Yoshihito, Tashiro, Yusuke, Kawai, Yugo, Nakata, Yoshitaka, Futatsusako, Hiroki, Sakamoto, Ayaka, Yasuhara, Naoko, Hashiguchi, Takao, Suzuki, Tateki, Kimura, Kanako, Sasaki, Jiei, Nakajima, Yukari, Yajima, Hisano, Irie, Takashi, Kawabata, Ryoko, Sasaki-Tabata, Kaori, Shimizu, Ryo, Monira Begum, M.S.T., Jonathan, Michael, Mugita, Yuka, Leong, Sharee, Takahashi, Otowa, Ichihara, Kimiko, Ueno, Takamasa, Motozono, Chihiro, Toyoda, Mako, Saito, Akatsuki, Kosaka, Anon, Kawano, Miki, Matsubara, Natsumi, Nishiuchi, Tomoko, Zahradnik, Jiri, Andrikopoulos, Prokopios, Padilla-Blanco, Miguel, Konar, Aditi, Fujita, Shigeru, Plianchaisuk, Arnon, Deguchi, Sayaka, Ito, Hayato, Nao, Naganori, Wang, Lei, Nasser, Hesham, Tamura, Tomokazu, Kimura, Izumi, Kashima, Yukie, Suzuki, Rigel, Suzuki, Saori, Kida, Izumi, Tsuda, Masumi, Oda, Yoshitaka, Hashimoto, Rina, Watanabe, Yukio, Uriu, Keiya, Yamasoba, Daichi, Guo, Ziyi, Hinay, Alfredo A., Jr., Kosugi, Yusuke, Chen, Luo, Pan, Lin, Kaku, Yu, Chu, Hin, Donati, Flora, Temmam, Sarah, Eloit, Marc, Yamamoto, Yuki, Nagamoto, Tetsuharu, Asakura, Hiroyuki, Nagashima, Mami, Sadamasu, Kenji, Yoshimura, Kazuhisa, Suzuki, Yutaka, Ito, Jumpei, Ikeda, Terumasa, Tanaka, Shinya, Matsuno, Keita, Fukuhara, Takasuke, Takayama, Kazuo, and Sato, Kei

Published
2024
Full Text
View/download PDF

2. The SARS-CoV-2 spike S375F mutation characterizes the Omicron BA.1 variant

Author

Kimura, Izumi, Yamasoba, Daichi, Nasser, Hesham, Zahradnik, Jiri, Kosugi, Yusuke, Wu, Jiaqi, Nagata, Kayoko, Uriu, Keiya, Tanaka, Yuri L., Ito, Jumpei, Shimizu, Ryo, Tan, Toong Seng, Butlertanaka, Erika P., Asakura, Hiroyuki, Sadamasu, Kenji, Yoshimura, Kazuhisa, Ueno, Takamasa, Takaori-Kondo, Akifumi, Schreiber, Gideon, Toyoda, Mako, Shirakawa, Kotaro, Irie, Takashi, Saito, Akatsuki, Nakagawa, So, Ikeda, Terumasa, and Sato, Kei

Published
2022
Full Text
View/download PDF

4. A panel of nanobodies recognizing conserved hidden clefts of all SARS-CoV-2 spike variants including Omicron

Author

Maeda, Ryota, Fujita, Junso, Konishi, Yoshinobu, Kazuma, Yasuhiro, Yamazaki, Hiroyuki, Anzai, Itsuki, Watanabe, Tokiko, Yamaguchi, Keishi, Kasai, Kazuki, Nagata, Kayoko, Yamaoka, Yutaro, Miyakawa, Kei, Ryo, Akihide, Shirakawa, Kotaro, Sato, Kei, Makino, Fumiaki, Matsuura, Yoshiharu, Inoue, Tsuyoshi, Imura, Akihiro, Namba, Keiichi, and Takaori-Kondo, Akifumi

Published
2022
Full Text
View/download PDF

5. Virological characteristics of a SARS-CoV-2-related bat coronavirus, BANAL-20-236

Author

Fujita, Shigeru, primary, Plianchaisuk, Arnon, additional, Deguchi, Sayaka, additional, Ito, Hayato, additional, Nao, Naganori, additional, Wang, Lei, additional, Nasser, Hesham, additional, Tamura, Tomokazu, additional, Kimura, Izumi, additional, Kashima, Yukie, additional, Suzuki, Rigel, additional, Suzuki, Saori, additional, Kida, Izumi, additional, Tsuda, Masumi, additional, Oda, Yoshitaka, additional, Hashimoto, Rina, additional, Watanabe, Yukio, additional, Uriu, Keiya, additional, Yamasoba, Daichi, additional, Guo, Ziyi, additional, Hinay, Alfredo A., additional, Kosugi, Yusuke, additional, Chen, Luo, additional, Pan, Lin, additional, Kaku, Yu, additional, Chu, Hin, additional, Donati, Flora, additional, Temmam, Sarah, additional, Eloit, Marc, additional, Yamamoto, Yuki, additional, Nagamoto, Tetsuharu, additional, Asakura, Hiroyuki, additional, Nagashima, Mami, additional, Sadamasu, Kenji, additional, Yoshimura, Kazuhisa, additional, Suzuki, Yutaka, additional, Sawa, Hirofumi, additional, Mizuma, Keita, additional, Li, Jingshu, additional, Mimura, Yume, additional, Ohari, Yuma, additional, Tsubo, Tomoya, additional, Ferdous, Zannatul, additional, Shishido, Kenji, additional, Mohri, Hiromi, additional, Iida, Miki, additional, Tsujino, Shuhei, additional, Misawa, Naoko, additional, Usui, Kaoru, additional, Saikruang, Wilaiporn, additional, Lytras, Spyridon, additional, Kawakubo, Shusuke, additional, Nishumura, Luca, additional, Mendoza Tolentino, Jarel Elgin, additional, Li, Wenye, additional, Yo, Maximilian Stanley, additional, Horinaka, Kio, additional, Suganami, Mai, additional, Chiba, Mika, additional, Yoshimura, Ryo, additional, Yasuda, Kyoko, additional, Iida, Keiko, additional, Strange, Adam Patrick, additional, Ohsumi, Naomi, additional, Tanaka, Shiho, additional, Ogawa, Eiko, additional, Okumura, Kaho, additional, Fukuda, Tsuki, additional, Osujo, Rina, additional, Yoshida, Isao, additional, Nakagawa, So, additional, Takaori-Kondo, Akifumi, additional, Shirakawa, Kotaro, additional, Nagata, Kayoko, additional, Nomura, Ryosuke, additional, Horisawa, Yoshihito, additional, Tashiro, Yusuke, additional, Kawai, Yugo, additional, Nakata, Yoshitaka, additional, Futatsusako, Hiroki, additional, Sakamoto, Ayaka, additional, Yasuhara, Naoko, additional, Hashiguchi, Takao, additional, Suzuki, Tateki, additional, Kimura, Kanako, additional, Sasaki, Jiei, additional, Nakajima, Yukari, additional, Yajima, Hisano, additional, Irie, Takashi, additional, Kawabata, Ryoko, additional, Sasaki-Tabata, Kaori, additional, Shimizu, Ryo, additional, Monira Begum, M.S.T., additional, Jonathan, Michael, additional, Mugita, Yuka, additional, Leong, Sharee, additional, Takahashi, Otowa, additional, Ichihara, Kimiko, additional, Ueno, Takamasa, additional, Motozono, Chihiro, additional, Toyoda, Mako, additional, Saito, Akatsuki, additional, Kosaka, Anon, additional, Kawano, Miki, additional, Matsubara, Natsumi, additional, Nishiuchi, Tomoko, additional, Zahradnik, Jiri, additional, Andrikopoulos, Prokopios, additional, Padilla-Blanco, Miguel, additional, Konar, Aditi, additional, Ito, Jumpei, additional, Ikeda, Terumasa, additional, Tanaka, Shinya, additional, Matsuno, Keita, additional, Fukuhara, Takasuke, additional, Takayama, Kazuo, additional, and Sato, Kei, additional

Published
2024
Full Text
View/download PDF

6. Protein kinase A inhibits tumor mutator APOBEC3B through phosphorylation

Author

Matsumoto, Tadahiko, Shirakawa, Kotaro, Yokoyama, Masaru, Fukuda, Hirofumi, Sarca, Anamaria Daniela, Koyabu, Sukenao, Yamazaki, Hiroyuki, Kazuma, Yasuhiro, Matsui, Hiroyuki, Maruyama, Wataru, Nagata, Kayoko, Tanabe, Fumiko, Kobayashi, Masayuki, Shindo, Keisuke, Morishita, Ryo, Sato, Hironori, and Takaori-Kondo, Akifumi

Published
2019
Full Text
View/download PDF

7. Monitoring fusion kinetics of viral and target cell membranes in living cells using a SARS-CoV-2 spike-protein-mediated membrane fusion assay

Author

Nasser, Hesham, primary, Shimizu, Ryo, additional, Ito, Jumpei, additional, Saito, Akatsuki, additional, Sato, Kei, additional, Ikeda, Terumasa, additional, Matsuno, Keita, additional, Nao, Naganori, additional, Sawa, Hirofumi, additional, Kishimoto, Mai, additional, Tanaka, Shinya, additional, Tsuda, Masumi, additional, Wang, Lei, additional, Oda, Yoshikata, additional, Kato, Marie, additional, Ferdous, Zannatul, additional, Mouri, Hiromi, additional, Shishido, Kenji, additional, Fukuhara, Takasuke, additional, Tamura, Tomokazu, additional, Suzuki, Rigel, additional, Ito, Hayato, additional, Yamasoba, Daichi, additional, Kimura, Izumi, additional, Misawa, Naoko, additional, Uriu, Keiya, additional, Kosugi, Yusuke, additional, Fujita, Shigeru, additional, Suganami, Mai, additional, Chiba, Mika, additional, Yoshimura, Ryo, additional, Nakagawa, So, additional, Wu, Jiaqi, additional, Takaori-Kondo, Akifumi, additional, Shirakawa, Kotaro, additional, Nagata, Kayoko, additional, Kazuma, Yasuhiro, additional, Nomura, Ryosuke, additional, Horisawa, Yoshihito, additional, Tashiro, Yusuke, additional, Kawai, Yugo, additional, Irie, Takashi, additional, Kawabata, Ryoko, additional, Begum, MST Monira, additional, Takahashi, Otowa, additional, Ichihara, Kimiko, additional, Ueno, Takamasa, additional, Motozono, Chihiro, additional, Toyoda, Mako, additional, Tanaka, Yuri L., additional, Butlertanaka, Erika P., additional, Shofa, Maya, additional, Takayama, Kazuo, additional, Hashimoto, Rina, additional, Deguchi, Sayaka, additional, Hashiguchi, Takao, additional, Suzuki, Tateki, additional, Kimura, Kanako, additional, Sasaki, Jiei, additional, Nakajima, Yukari, additional, and Tabata, Kaori, additional

Published
2022
Full Text
View/download PDF

8. Virological characteristics of the SARS-CoV-2 Omicron BA.2.75 variant

Author

Saito, Akatsuki, primary, Tamura, Tomokazu, additional, Zahradnik, Jiri, additional, Deguchi, Sayaka, additional, Tabata, Koshiro, additional, Anraku, Yuki, additional, Kimura, Izumi, additional, Ito, Jumpei, additional, Yamasoba, Daichi, additional, Nasser, Hesham, additional, Toyoda, Mako, additional, Nagata, Kayoko, additional, Uriu, Keiya, additional, Kosugi, Yusuke, additional, Fujita, Shigeru, additional, Shofa, Maya, additional, Monira Begum, MST, additional, Shimizu, Ryo, additional, Oda, Yoshitaka, additional, Suzuki, Rigel, additional, Ito, Hayato, additional, Nao, Naganori, additional, Wang, Lei, additional, Tsuda, Masumi, additional, Yoshimatsu, Kumiko, additional, Kuramochi, Jin, additional, Kita, Shunsuke, additional, Sasaki-Tabata, Kaori, additional, Fukuhara, Hideo, additional, Maenaka, Katsumi, additional, Yamamoto, Yuki, additional, Nagamoto, Tetsuharu, additional, Asakura, Hiroyuki, additional, Nagashima, Mami, additional, Sadamasu, Kenji, additional, Yoshimura, Kazuhisa, additional, Ueno, Takamasa, additional, Schreiber, Gideon, additional, Takaori-Kondo, Akifumi, additional, Shirakawa, Kotaro, additional, Sawa, Hirofumi, additional, Irie, Takashi, additional, Hashiguchi, Takao, additional, Takayama, Kazuo, additional, Matsuno, Keita, additional, Tanaka, Shinya, additional, Ikeda, Terumasa, additional, Fukuhara, Takasuke, additional, and Sato, Kei, additional

Published
2022
Full Text
View/download PDF

9. Intratracheal trimerized nanobody cocktail administration suppresses weight loss and prolongs survival of SARS-CoV-2 infected mice

Author

80728270, Nagata, Kayoko, Utsumi, Daichi, Asaka, Masamitsu N., Maeda, Ryota, Shirakawa, Kotaro, Kazuma, Yasuhiro, Nomura, Ryosuke, Horisawa, Yoshihito, Yanagida, Yohei, Kawai, Yugo, Sato, Kei, Yamaoka, Yutaro, Miyakawa, Kei, Ryo, Akihide, Yasutomi, Yasuhiro, Imura, Akihiro, Takaori-Kondo, Akifumi, 80728270, Nagata, Kayoko, Utsumi, Daichi, Asaka, Masamitsu N., Maeda, Ryota, Shirakawa, Kotaro, Kazuma, Yasuhiro, Nomura, Ryosuke, Horisawa, Yoshihito, Yanagida, Yohei, Kawai, Yugo, Sato, Kei, Yamaoka, Yutaro, Miyakawa, Kei, Ryo, Akihide, Yasutomi, Yasuhiro, Imura, Akihiro, and Takaori-Kondo, Akifumi

Abstract

BACKGROUND: SARS-CoV-2 Omicron variants are highly resistant to vaccine-induced immunity and human monoclonal antibodies. METHODS: We previously reported that two nanobodies, P17 and P86, potently neutralize SARS-CoV-2 VOCs. In this study, we modified these nanobodies into trimers, called TP17 and TP86 and tested their neutralization activities against Omicron BA.1 and subvariant BA.2 using pseudovirus assays. Next, we used TP17 and TP86 nanobody cocktail to treat ACE2 transgenic mice infected with lethal dose of SARS-CoV-2 strains, original, Delta and Omicron BA.1. RESULTS: Here, we demonstrate that a novel nanobody TP86 potently neutralizes both BA.1 and BA.2 Omicron variants, and that the TP17 and TP86 nanobody cocktail broadly neutralizes in vitro all VOCs as well as original strain. Furthermore, intratracheal administration of this nanobody cocktail suppresses weight loss and prolongs survival of human ACE2 transgenic mice infected with SARS-CoV-2 strains, original, Delta and Omicron BA.1. CONCLUSIONS: Intratracheal trimerized nanobody cocktail administration suppresses weight loss and prolongs survival of SARS-CoV-2 infected mice.

Published
2022

10. Bortezomib-cyclophosphamide-dexamethasone induction/consolidation and bortezomib maintenance for transplant-eligible newly diagnosed multiple myeloma: phase 2 multicenter trial

Author

30636311, 70217933, Muranushi, Hiroyuki, Kanda, Junya, Kobayashi, Masayuki, Maeda, Takeshi, Kitano, Toshiyuki, Tsuji, Masaaki, Ueda, Yasunori, Ishikawa, Takayuki, Nohgawa, Masaharu, Watanabe, Mitsumasa, Imada, Kazunori, Moriguchi, Toshinori, Itoh, Mitsuru, Ohno, Hitoshi, Yonezawa, Akihito, Hirata, Hirokazu, Arima, Nobuyoshi, Asagoe, Kohsuke, Anzai, Naoyuki, Nagata, Kayoko, Yasuno, Shinji, Kuwabara, Yoshihiro, Kitao, Hiromi, Kim, Ihhwa, Kawagishi, Kiyomi, Ueshima, Kenji, Tominari, Shinjiro, Nakayama, Takeo, Yamashita, Kouhei, Takaori-Kondo, Akifumi, 30636311, 70217933, Muranushi, Hiroyuki, Kanda, Junya, Kobayashi, Masayuki, Maeda, Takeshi, Kitano, Toshiyuki, Tsuji, Masaaki, Ueda, Yasunori, Ishikawa, Takayuki, Nohgawa, Masaharu, Watanabe, Mitsumasa, Imada, Kazunori, Moriguchi, Toshinori, Itoh, Mitsuru, Ohno, Hitoshi, Yonezawa, Akihito, Hirata, Hirokazu, Arima, Nobuyoshi, Asagoe, Kohsuke, Anzai, Naoyuki, Nagata, Kayoko, Yasuno, Shinji, Kuwabara, Yoshihiro, Kitao, Hiromi, Kim, Ihhwa, Kawagishi, Kiyomi, Ueshima, Kenji, Tominari, Shinjiro, Nakayama, Takeo, Yamashita, Kouhei, and Takaori-Kondo, Akifumi

Abstract

[Objectives:] We conducted a phase II trial to prospectively evaluate the efficacy and safety of bortezomib-cyclophosphamide-dexamethasone (VCD) induction, autologous stem cell transplantation (ASCT), VCD consolidation, and bortezomib maintenance in transplant-eligible newly diagnosed multiple myeloma (NDMM) patients in Japan (UMIN000010542). [Methods:] From 2013 to 2016, 42 patients with a median age of 58 (range 42–65) years with NDMM were enrolled in 15 centers. The primary endpoint was the complete response (CR) /stringent CR (sCR) rate after transplantation, and overall/progression-free survival rates were also evaluated. [Results:] Following induction therapy, the overall response rate was obtained in 71% of patients, including a CR/sCR of 10% and a very good partial response (VGPR) of 26%. Twenty-six of the 42 patients completed ASCT following the protocol and CR/sCR and VGPR rate 100 days after ASCT was 26% and 17%, respectively. During consolidation therapy, 3 of the 24 patients achieved deeper responses. Eight of the 18 patients completed 2-year bortezomib maintenance without disease progression and grade 3/4 toxicities. Five patients were VGPR or partial response after ASCT but maintained response with 2-year bortezomib maintenance. Two-year overall and progression-free survival rates were 92.5% (95% confidence interval [CI]: 78.5%−97.5%) and 62.6% (95% CI: 45.8%−75.5%), respectively. Grade 3/4 toxicities (≥ 10%) included neutropenia (19%) and anemia (17%) in induction, and thrombocytopenia (29%) in consolidation. [Conclusion:] VCD induction/consolidation and bortezomib maintenance with ASCT for NDMM resulted in a high CR/sCR rate and provided good overall/progression-free survival in Japan.

Published
2022

11. Virological characteristics of the SARS-CoV-2 Omicron BA.2.75 variant

Author

80728270, 50632098, 10759509, Saito, Akatsuki, Tamura, Tomokazu, Zahradnik, Jiri, Deguchi, Sayaka, Tabata, Koshiro, Anraku, Yuki, Kimura, Izumi, Ito, Jumpei, Yamasoba, Daichi, Nasser, Hesham, Toyoda, Mako, Nagata, Kayoko, Uriu, Keiya, Kosugi, Yusuke, Fujita, Shigeru, Shofa, Maya, Monira Begum, M.S.T., Shimizu, Ryo, Oda, Yoshitaka, Suzuki, Rigel, Ito, Hayato, Nao, Naganori, Wang, Lei, Tsuda, Masumi, Yoshimatsu, Kumiko, Kuramochi, Jin, Kita, Shunsuke, Sasaki-Tabata, Kaori, Fukuhara, Hideo, Maenaka, Katsumi, Yamamoto, Yuki, Nagamoto, Tetsuharu, Asakura, Hiroyuki, Nagashima, Mami, Sadamasu, Kenji, Yoshimura, Kazuhisa, Ueno, Takamasa, Schreiber, Gideon, Takaori-Kondo, Akifumi, The Genotype to Phenotype Japan (G2P-Japan) Consortium, Shirakawa, Kotaro, Sawa, Hirofumi, Irie, Takashi, Hashiguchi, Takao, Takayama, Kazuo, Matsuno, Keita, Tanaka, Shinya, Ikeda, Terumasa, Fukuhara, Takasuke, Sato, Kei, 80728270, 50632098, 10759509, Saito, Akatsuki, Tamura, Tomokazu, Zahradnik, Jiri, Deguchi, Sayaka, Tabata, Koshiro, Anraku, Yuki, Kimura, Izumi, Ito, Jumpei, Yamasoba, Daichi, Nasser, Hesham, Toyoda, Mako, Nagata, Kayoko, Uriu, Keiya, Kosugi, Yusuke, Fujita, Shigeru, Shofa, Maya, Monira Begum, M.S.T., Shimizu, Ryo, Oda, Yoshitaka, Suzuki, Rigel, Ito, Hayato, Nao, Naganori, Wang, Lei, Tsuda, Masumi, Yoshimatsu, Kumiko, Kuramochi, Jin, Kita, Shunsuke, Sasaki-Tabata, Kaori, Fukuhara, Hideo, Maenaka, Katsumi, Yamamoto, Yuki, Nagamoto, Tetsuharu, Asakura, Hiroyuki, Nagashima, Mami, Sadamasu, Kenji, Yoshimura, Kazuhisa, Ueno, Takamasa, Schreiber, Gideon, Takaori-Kondo, Akifumi, The Genotype to Phenotype Japan (G2P-Japan) Consortium, Shirakawa, Kotaro, Sawa, Hirofumi, Irie, Takashi, Hashiguchi, Takao, Takayama, Kazuo, Matsuno, Keita, Tanaka, Shinya, Ikeda, Terumasa, Fukuhara, Takasuke, and Sato, Kei

Abstract

The SARS-CoV-2 Omicron BA.2.75 variant emerged in May 2022. BA.2.75 is a BA.2 descendant but is phylogenetically distinct from BA.5, the currently predominant BA.2 descendant. Here, we show that BA.2.75 has a greater effective reproduction number and different immunogenicity profile than BA.5. We determined the sensitivity of BA.2.75 to vaccinee and convalescent sera as well as a panel of clinically available antiviral drugs and antibodies. Antiviral drugs largely retained potency but antibody sensitivity varied depending on several key BA.2.75-specific substitutions. The BA.2.75 spike exhibited a profoundly higher affinity for its human receptor, ACE2. Additionally, the fusogenicity, growth efficiency in human alveolar epithelial cells, and intrinsic pathogenicity in hamsters of BA.2.75 were greater than those of BA.2. Our multilevel investigations suggest that BA.2.75 acquired virological properties independent of BA.5, and the potential risk of BA.2.75 to global health is greater than that of BA.5.

Published
2022

12. Virological characteristics of the SARS-CoV-2 Omicron BA.2 spike

Author

Yamasoba, Daichi, primary, Kimura, Izumi, additional, Nasser, Hesham, additional, Morioka, Yuhei, additional, Nao, Naganori, additional, Ito, Jumpei, additional, Uriu, Keiya, additional, Tsuda, Masumi, additional, Zahradnik, Jiri, additional, Shirakawa, Kotaro, additional, Suzuki, Rigel, additional, Kishimoto, Mai, additional, Kosugi, Yusuke, additional, Kobiyama, Kouji, additional, Hara, Teppei, additional, Toyoda, Mako, additional, Tanaka, Yuri L., additional, Butlertanaka, Erika P., additional, Shimizu, Ryo, additional, Ito, Hayato, additional, Wang, Lei, additional, Oda, Yoshitaka, additional, Orba, Yasuko, additional, Sasaki, Michihito, additional, Nagata, Kayoko, additional, Yoshimatsu, Kumiko, additional, Asakura, Hiroyuki, additional, Nagashima, Mami, additional, Sadamasu, Kenji, additional, Yoshimura, Kazuhisa, additional, Kuramochi, Jin, additional, Seki, Motoaki, additional, Fujiki, Ryoji, additional, Kaneda, Atsushi, additional, Shimada, Tadanaga, additional, Nakada, Taka-aki, additional, Sakao, Seiichiro, additional, Suzuki, Takuji, additional, Ueno, Takamasa, additional, Takaori-Kondo, Akifumi, additional, Ishii, Ken J., additional, Schreiber, Gideon, additional, Sawa, Hirofumi, additional, Saito, Akatsuki, additional, Irie, Takashi, additional, Tanaka, Shinya, additional, Matsuno, Keita, additional, Fukuhara, Takasuke, additional, Ikeda, Terumasa, additional, and Sato, Kei, additional

Published
2022
Full Text
View/download PDF

13. Characteristics of the SARS-CoV-2 omicron HK.3 variant harbouring the FLip substitution

Author

Misawa, Naoko, Guo, Ziyi, Tolentino, Jarel Elgin M, Fujita, Shigeru, Pan, Lin, Suganami, Mai, Chiba, Mika, Yoshimura, Ryo, Yasuda, Kyoko, Iida, Keiko, Ohsumi, Naomi, Strange, Adam P, Tanaka, Shiho, Fukuhara, Takasuke, Tamura, Tomokazu, Suzuki, Rigel, Suzuki, Saori, Ito, Hayato, Matsuno, Keita, Sawa, Hirofumi, Nao, Naganori, Tanaka, Shinya, Tsuda, Masumi, Wang, Lei, Oda, Yoshikata, Ferdous, Zannatul, Shishido, Kenji, Nakagawa, So, Shirakawa, Kotaro, Takaori-Kondo, Akifumi, Nagata, Kayoko, Nomura, Ryosuke, Horisawa, Yoshihito, Tashiro, Yusuke, Kawai, Yugo, Takayama, Kazuo, Hashimoto, Rina, Deguchi, Sayaka, Watanabe, Yukio, Sakamoto, Ayaka, Yasuhara, Naoko, Hashiguchi, Takao, Suzuki, Tateki, Kimura, Kanako, Sasaki, Jiei, Nakajima, Yukari, Yajima, Hisano, Irie, Takashi, Kawabata, Ryoko, Tabata, Kaori, Ikeda, Terumasa, Nasser, Hesham, Shimizu, Ryo, Begum, MST Monira, Jonathan, Michael, Mugita, Yuka, Takahashi, Otowa, Ichihara, Kimiko, Ueno, Takamasa, Motozono, Chihiro, Toyoda, Mako, Saito, Akatsuki, Shofa, Maya, Shibatani, Yuki, Nishiuchi, Tomoko, Kosugi, Yusuke, Plianchaisuk, Arnon, Putri, Olivia, Uriu, Keiya, Kaku, Yu, Hinay, Alfredo A, Jr, Chen, Luo, Kuramochi, Jin, Sadamasu, Kenji, Yoshimura, Kazuhisa, Asakura, Hiroyuki, Nagashima, Mami, Ito, Jumpei, and Sato, Kei

Published
2024
Full Text
View/download PDF

14. Bortezomib-cyclophosphamide-dexamethasone induction/consolidation and bortezomib maintenance for transplant-eligible newly diagnosed multiple myeloma: phase 2 multicenter trial

Author

Muranushi, Hiroyuki, primary, Kanda, Junya, additional, Kobayashi, Masayuki, additional, Maeda, Takeshi, additional, Kitano, Toshiyuki, additional, Tsuji, Masaaki, additional, Ueda, Yasunori, additional, Ishikawa, Takayuki, additional, Nohgawa, Masaharu, additional, Watanabe, Mitsumasa, additional, Imada, Kazunori, additional, Moriguchi, Toshinori, additional, Itoh, Mitsuru, additional, Ohno, Hitoshi, additional, Yonezawa, Akihito, additional, Hirata, Hirokazu, additional, Arima, Nobuyoshi, additional, Asagoe, Kohsuke, additional, Anzai, Naoyuki, additional, Nagata, Kayoko, additional, Yasuno, Shinji, additional, Kuwabara, Yoshihiro, additional, Kitao, Hiromi, additional, Kim, Ihhwa, additional, Kawagishi, Kiyomi, additional, Ueshima, Kenji, additional, Tominari, Shinjiro, additional, Nakayama, Takeo, additional, Yamashita, Kouhei, additional, and Takaori-Kondo, Akifumi, additional

Published
2022
Full Text
View/download PDF

15. Critical role of PP2A-B56 family protein degradation in HIV-1 Vif mediated G2 cell cycle arrest

Author

80728270, Nagata, Kayoko, Shindo, Keisuke, Matsui, Yusuke, Shirakawa, Kotaro, Takaori-Kondo, Akifumi, 80728270, Nagata, Kayoko, Shindo, Keisuke, Matsui, Yusuke, Shirakawa, Kotaro, and Takaori-Kondo, Akifumi

Abstract

HIV-1 Vif forms an E3 ubiquitin ligase complex with host proteins to counteract host restrictive APOBEC3, and is also known to accumulate infected cells at the G2 phase to promote viral replication. However, the underlying mechanism of how Vif induces G2 arrest is not fully understood, and more specifically, direct target molecules of G2 arrest have not been identified. Here we show that degradation of B56 family proteins (PP2A-B56), one of the regulatory subunits of protein phosphatase 2A, is critical for the Vif-induced G2 arrest. NL4-3 Vif caused degradation of PP2A-B56, and complementation of PP2A-B56 overcome the Vif-induced arrest. Supportively, knockdown of PPP2R5D, one of PP2A-B56, by siRNA itself induced cell cycle arrest of non-infected cells. We also identified Vif residues I31 and R or K33 are determinants for inducing G2 arrest, and Vif variants that did not cause G2 arrest did not induce PPP2R5D degradation, although it maintain the ability to induce APOBEC3G degradation, showing strong correlation between Vif-induced arrest and PP2A-B56 degradation. In a sequence database of HIV-1 isolates, Vif strains harboring residues that presumably induce cell cycle arrest are approximately 43%, suggesting Vif-induced G2 arrest contributes to HIV-1 infection in vivo and spread. Our data help understand the mechanism of Vif-mediated arrest, and gain insights into general cell cycle regulation.

Published
2020

17. Monitoring fusion kinetics of viral and target cell membranes in living cells using a SARS-CoV-2 spike-protein-mediated membrane fusion assay

Author

Matsuno, Keita, Nao, Naganori, Sawa, Hirofumi, Kishimoto, Mai, Tanaka, Shinya, Tsuda, Masumi, Wang, Lei, Oda, Yoshikata, Kato, Marie, Ferdous, Zannatul, Mouri, Hiromi, Shishido, Kenji, Fukuhara, Takasuke, Tamura, Tomokazu, Suzuki, Rigel, Ito, Hayato, Yamasoba, Daichi, Kimura, Izumi, Misawa, Naoko, Uriu, Keiya, Kosugi, Yusuke, Fujita, Shigeru, Suganami, Mai, Chiba, Mika, Yoshimura, Ryo, Nakagawa, So, Wu, Jiaqi, Takaori-Kondo, Akifumi, Shirakawa, Kotaro, Nagata, Kayoko, Kazuma, Yasuhiro, Nomura, Ryosuke, Horisawa, Yoshihito, Tashiro, Yusuke, Kawai, Yugo, Irie, Takashi, Kawabata, Ryoko, Begum, MST Monira, Takahashi, Otowa, Ichihara, Kimiko, Ueno, Takamasa, Motozono, Chihiro, Toyoda, Mako, Tanaka, Yuri L., Butlertanaka, Erika P., Shofa, Maya, Takayama, Kazuo, Hashimoto, Rina, Deguchi, Sayaka, Hashiguchi, Takao, Suzuki, Tateki, Kimura, Kanako, Sasaki, Jiei, Nakajima, Yukari, Tabata, Kaori, Nasser, Hesham, Shimizu, Ryo, Ito, Jumpei, Saito, Akatsuki, Sato, Kei, and Ikeda, Terumasa

Published
2022
Full Text
View/download PDF

18. A screening for DNA damage response molecules that affect HIV-1 infection

Author

80728270, Yoshinaga, Noriyoshi, Shindo, Keisuke, Matsui, Yusuke, Takiuchi, Yoko, Fukuda, Hirofumi, Nagata, Kayoko, Shirakawa, Kotaro, Kobayashi, Masayuki, Takeda, Shunichi, Takaori-Kondo, Akifumi, 80728270, Yoshinaga, Noriyoshi, Shindo, Keisuke, Matsui, Yusuke, Takiuchi, Yoko, Fukuda, Hirofumi, Nagata, Kayoko, Shirakawa, Kotaro, Kobayashi, Masayuki, Takeda, Shunichi, and Takaori-Kondo, Akifumi

Abstract

Host DNA damage response molecules affect retroviral infection, as DNA intermediates of the viruses play essential roles in the viral life cycles. Although several such molecules have been reported, interactions between HIV-1 and host DNA damage response molecules have not been fully elucidated. To screen DNA damage response molecules that might affect HIV-1 infection, a set of 32 DNA-repair-deficient DT40 isogenic mutant cells were tested for HIV-1 infectivity. Seven out of the 32 clones showed less than 50% infectivity compared to parental DT40 cells, implying that DNA repair molecules deficient in these cells might support HIV-1 infection. Of these, EXO1 −/−, TP53BP1 −/− and WRN −/− cells showed more than twofold accumulation of two long terminal repeat circles and less than 50% integrated proviral DNA in quantitative-PCR analyses, indicating that the integration step is impaired. RAD18 −/− cells showed twofold higher HIV-1 infectivity and increased reverse transcription products at earlier time points, suggesting that RAD18 suppresses reverse transcription. The HIV-1 suppressive effects of RAD18 were confirmed by over-expression and knockdown experiments in human cells. L274P, a DNA-binding-impaired mutant of RAD18, showed impaired HIV-1 suppression and DNA binding, suggesting that binding HIV-1 DNA intermediates is critical for RAD18 to suppress reverse transcription and HIV-1 infection. Our data help understand interactions between host DNA damage response molecules and viral DNA.

Published
2019

19. HTLV-1 bZIP factor suppresses TDP1 expression through inhibition of NRF-1 in adult T-cell leukemia

Author

Takiuchi, Yoko, primary, Kobayashi, Masayuki, additional, Tada, Kohei, additional, Iwai, Fumie, additional, Sakurada, Maki, additional, Hirabayashi, Shigeki, additional, Nagata, Kayoko, additional, Shirakawa, Kotaro, additional, Shindo, Keisuke, additional, Yasunaga, Jun-ichirou, additional, Murakawa, Yasuhiro, additional, Rajapakse, Vinodh, additional, Pommier, Yves, additional, Matsuoka, Masao, additional, and Takaori-Kondo, Akifumi, additional

Published
2017
Full Text
View/download PDF

21. Abacavir, an anti–HIV-1 drug, targets TDP1-deficient adult T cell leukemia

Author

Tada, Kohei, primary, Kobayashi, Masayuki, additional, Takiuchi, Yoko, additional, Iwai, Fumie, additional, Sakamoto, Takashi, additional, Nagata, Kayoko, additional, Shinohara, Masanobu, additional, Io, Katsuhiro, additional, Shirakawa, Kotaro, additional, Hishizawa, Masakatsu, additional, Shindo, Keisuke, additional, Kadowaki, Norimitsu, additional, Hirota, Kouji, additional, Yamamoto, Junpei, additional, Iwai, Shigenori, additional, Sasanuma, Hiroyuki, additional, Takeda, Shunichi, additional, and Takaori-Kondo, Akifumi, additional

Published
2015
Full Text
View/download PDF

22. CKIP-1 Is an Intrinsic Negative Regulator of T-Cell Activation through an Interaction with CARMA1

Author

Sakamoto, Takashi, primary, Kobayashi, Masayuki, additional, Tada, Kohei, additional, Shinohara, Masanobu, additional, Io, Katsuhiro, additional, Nagata, Kayoko, additional, Iwai, Fumie, additional, Takiuchi, Yoko, additional, Arai, Yasuyuki, additional, Yamashita, Kouhei, additional, Shindo, Keisuke, additional, Kadowaki, Norimitsu, additional, Koyanagi, Yoshio, additional, and Takaori-Kondo, Akifumi, additional

Published
2014
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results